Sclerostin within the Chronic Kidney Disease spectrum
2020
Abstract Sclerostin is sometimes presented as a promising biomarker in assessing bone health both in the general population and chronic kidney disease patients. However, it is still unclear whether it has any true added value compared to existing bone biomarkers in predicting bone turnover and/or bone density in chronic kidney disease patients. A wealth of papers has been published to evaluate the association between sclerostin and vascular calcifications development or even as prognostic biomarker for mortality, but often with conflicting results. Standardization and harmonization of analytical techniques is a prerequisite to advance clinical knowledge in sclerostin.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
86
References
4
Citations
NaN
KQI